Table 2.
Comparison of clinical outcomes between ciclesonide and standard care groups.
| Ciclesonide Group (n = 35) | Standard Care Group (n = 26) | p-Value | Adjusted OR (95% CI) of Ciclesonide Treatment | |
|---|---|---|---|---|
| Clinical failure rate, No. (%) | 1 (2.9) | 5 (19.2) | 0.034 | 0.026 (0.001–0.845) |
| Clinical improvement rate at day 7, No. (%) | 19 (54.3) | 15 (57.7) | 0.793 | - |
| Clinical improvement rate at day 10, No. (%) | 21 (60.0) | 14 (53.8) | 0.794 | - |
| Clinical improvement rate at day 14, No. (%) | 26 (74.3) | 14 (53.8) | 0.111 | - |
| Virologic eradication rate at day 7, No. (%) | 2/34 (5.9) a | 0/22 (0) b | 0.247 | - |
| Virologic eradication rate at day 10, No. (%) | 4/33 (12.1) a | 0/22 (0) b | 0.090 | - |
| Virologic eradication rate at day 14, No. (%) | 10/31 (32.3) a | 1/20 (5.0) b | 0.021 | 12.194 (1.187–125.240) |
| Duration of hospitalization, mean days ± SD | 19.1 ± 7.7 | 19.5 ± 7.4 | 0.839 | - |
SD, standard deviation; OR, odds ratio; CI, confidence interval. a One patient was excluded at days 7, 10, and 14 because of clinical failure. In addition, one patient was excluded at day 10, and two more patients were excluded at day 14 because of early discharge with clinical improvement; respiratory specimens were not available. b Four patients were excluded at days 7 and 10, while five patients were excluded at day 14 because of clinical failure. In addition, one more patient was excluded at day 14 because of early discharge with clinical improvement; respiratory specimens were not available.